Editorial Perspectives On Cell Line Development

  1. Who Said mAbs Were Easy? 4/27/2022

    Under the leadership of CEO Mondher Mahjoubi, M.D., oncology-focused biotech Innate Pharma is developing therapeutic antibodies that harness the immune system to fight cancer. The company is making strides with some next-gen, complex tri- and tetra-specific antibodies—and Dr. Mahjoubi isn't afraid to face the CMC challenges that come with the job. 

  2. Ocular + Auditory Cell Therapies: Lineage Cell Therapeutics 2.0 4/25/2022

    On the heels of a lucrative deal with Roche/Genentech for its Phase I/IIa dry age-related macular degeneration candidate, Lineage Cell Therapeutics is fording new waters with a promising auditory neuropathy spectrum disorder candidate. CEO Brian Culley shares the strategy.

  3. Inside The Allogeneic NK Cell Therapy Effort 3/21/2022

    With its genetically engineered induced pluripotent stem cell-derived allogeneic natural killer cell technology, Shoreline Biosciences aims to overcome what Chairman and CEO Kleanthis Xanthopoulos calls the tallest barrier in the space: patient accessibility.

  4. Regenerating The Vasculature With Bioengineered Human Tissue 2/23/2022

    With two phase 3 trials resuting in its bioengineered blood vessels being implanted in some 460 human patients, regenerative medicine pioneer Humacyte is finding its footing in the $150 billion vascular repair, reconstruction, and replacement market. Now it's preparing to reinvent treatment for Type 1 Diabetes.

  5. A Drug Discovery Alliance For The Ages 2/14/2022

    With the renewal of their Collaborative Research Agreement, the La Jolla Institute for Immunology and Kyowa Kirin North America extended a more than 30-year partnership that continues to bear fruit. As many good and longstanding friendships do, it all started with beer. Here’s why the collaboration stands the test of time.

  6. Vaccine Manufacturing: Chasing COVID's Long Tail 1/31/2022

    A host of biopharma companies continue to pour resources into coronavirus vaccine candidates. Among them, iBio stands out with a unique target region (hint: it’s not a spike protein) and an even more unique manufacturing paradigm (hint: it’s not mRNA). 

  7. Reengineering Biologics Manufacturing And Access With Spirulina 1/24/2022

    The “democratization” of biologics requires cost, time, and resource elimination from cell culture to administration and every step in between. Here’s how one innovative emerging biotech is leveraging one of the world’s oldest and most prolific organisms to that end.

  8. Big Bio: Inside SILS' New Stake In Biocon 9/18/2021

    The sum of government vaccine mandates and a pandemic that’s turning endemic make simple math out of a $5 billion big bio deal.

  9. New ADC Linker Tech Shows Efficacy, Safety Advantages 9/8/2021

    Araris Biotech AG CEO and co-founder Dr. Philipp Spycher says his company’s linker technology eliminates the antibody engineering requirement, is more stable and efficacious, and requires far less drug payload than those currently in use. Now it’s building a pipeline and seeking partnerships.

  10. Developing A Cure For Diabetes Type 1 7/21/2021

    Ulf Hannelius, Ph.D. is leading a charge at Diamyd Medical with a singular mission: curing type 1 diabetes. The Business of Biotech caught up with him for deep dive into the company’s progress.